TSHA Taysha Gene Therapies Inc
Price (delayed)
$2.16
Market cap
$442.68M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.2
Enterprise value
$323.3M
Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to
Highlights
The company's equity has surged by 102% QoQ
Taysha Gene Therapies's EPS has surged by 91% YoY and by 59% QoQ
The gross profit has increased by 34% YoY but it has decreased by 9% QoQ
Taysha Gene Therapies's revenue has increased by 34% YoY but it has decreased by 9% QoQ
Key stats
What are the main financial stats of TSHA
Market
Valuations
Earnings
Shares outstanding
204.94M
Market cap
$442.68M
Enterprise value
$323.3M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.71
Price to sales (P/S)
39.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.11
Revenue
$12.87M
EBIT
-$112.1M
EBITDA
-$109.55M
Free cash flow
-$75.73M
Per share
Balance sheet
Liquidity
EPS
-$0.2
Free cash flow per share
-$0.33
Book value per share
$0.58
Revenue per share
$0.06
TBVPS
$0.86
Total assets
$200.39M
Total liabilities
$91.53M
Debt
$55.97M
Equity
$108.87M
Working capital
$144.29M
Debt to equity
0.51
Current ratio
5.22
Quick ratio
5.13
Net debt/EBITDA
1.09
Margins
Efficiency
Dividend
EBITDA margin
-851%
Gross margin
100%
Net margin
-888.2%
Operating margin
-606.9%
Return on assets
-63.4%
Return on equity
-242.6%
Return on invested capital
-922.9%
Return on capital employed
-67.4%
Return on sales
-870.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TSHA stock price
How has the Taysha Gene Therapies stock price performed over time
Intraday
-5.68%
1 week
-5.68%
1 month
-4%
1 year
-34.35%
YTD
22.03%
QTD
-3.57%
Financial performance
How have Taysha Gene Therapies's revenue and profit performed over time
Revenue
$12.87M
Gross profit
$12.87M
Operating income
-$78.13M
Net income
-$114.34M
Gross margin
100%
Net margin
-888.2%
TSHA's operating margin has soared by 51% YoY but it is down by 7% QoQ
The operating income has increased by 35% year-on-year and by 2.6% since the previous quarter
The gross profit has increased by 34% YoY but it has decreased by 9% QoQ
Taysha Gene Therapies's revenue has increased by 34% YoY but it has decreased by 9% QoQ
Growth
What is Taysha Gene Therapies's growth rate over time
Valuation
What is Taysha Gene Therapies stock price valuation
P/E
N/A
P/B
3.71
P/S
39.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.11
Taysha Gene Therapies's EPS has surged by 91% YoY and by 59% QoQ
The company's equity has surged by 102% QoQ
Taysha Gene Therapies's revenue has increased by 34% YoY but it has decreased by 9% QoQ
TSHA's price to sales (P/S) is 29% more than its last 4 quarters average of 32.1
Efficiency
How efficient is Taysha Gene Therapies business performance
TSHA's ROE has soared by 78% since the previous quarter
Taysha Gene Therapies's return on assets has increased by 46% YoY and by 19% QoQ
Taysha Gene Therapies's return on sales has increased by 30% YoY but it has decreased by 8% QoQ
The return on invested capital has increased by 14% since the previous quarter
Dividends
What is TSHA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TSHA.
Financial health
How did Taysha Gene Therapies financials performed over time
The company's total assets is 119% higher than its total liabilities
The company's total assets has surged by 146% YoY and by 31% QoQ
Taysha Gene Therapies's quick ratio has surged by 56% QoQ
The debt is 49% less than the equity
Taysha Gene Therapies's debt to equity has surged by 133% YoY but it has shrunk by 54% QoQ
The company's equity has surged by 102% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.